CMN Weekly (4 April 2025) - Your Weekly CRISPR...
CMN Weekly
Apr. 4, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Sangamo Therapeutics
Main focus: Gene editing using zing-finger nucleases for novel gene-ediing and cell therapies.
Company stage: Clinical
Diseases: Solid graft transplantations, beta-thalassemia, sickle cell disease, inflammatory bowel disease, multiple sclerosis, solid tumours, haematological cancers
Genome editing technology: Zinc finger nucleases (ZNFs)
Funding stage: Public (NASDAQ:SGMO)
Location: South San Francisco, CA, USA
Website: https://www.sangamo.com/
Pipeline: https://www.sangamo.com/pipeline
Partners: Sanofi, Takeda Pharma, Novartis, Pfizer, Kite Pharma, Biogen
Sangamo Therapeutics is the only company solely focused on the development of zinc finger nucleases (ZFNs) as a tool for genetic engineering. The company applies the tool for both ex vivo and in vivo-based gene-editing therapies, as well as a tool for genome regulation. The company is currently sponsoring clinical trials for sickle cell disease and beta-thalassemia, where ZFNs are applied for gene editing. The company holds multiple substantial collaborations with companies such Pfizer, Biogen, Novartis, Takeda, Sanofi and Kite Pharma.
